Skip to content
Inciteful Med

Surveillance and Cancer Risks in PSC

Last updated:

People with Primary Sclerosing Cholangitis (PSC) have an increased risk of bile duct, gallbladder, and colon cancers. Strict adherence to a surveillance schedule—including MRCP imaging and CA 19-9 blood tests every 6 to 12 months—is essential for early cancer detection and improving long-term health outcomes.

Key Takeaways

  • • Patients with PSC have a 10% to 20% lifetime risk of developing cholangiocarcinoma (bile duct cancer).
  • • The gold standard for bile duct monitoring is an MRCP scan combined with a CA 19-9 blood test every 6 to 12 months.
  • • Gallbladder polyps carry a higher cancer risk in PSC patients and often require gallbladder removal if they reach 8mm or grow.
  • • Patients with both PSC and Inflammatory Bowel Disease (IBD) require an annual colonoscopy to monitor for colorectal cancer.
  • • Chromoendoscopy, which uses a special dye during a colonoscopy, is highly recommended to detect the flat precancerous lesions common in PSC patients.

One of the most important aspects of living with Primary Sclerosing Cholangitis (PSC) is proactive surveillance—a regular schedule of tests designed to catch complications, including cancer, as early as possible. While the risks are higher for PSC patients than for the general population, consistent monitoring allows for early intervention, which is the most effective way to improve long-term outcomes [1][2].

Understanding the Risks

PSC is associated with an increased risk of several types of cancer, primarily affecting the liver, bile ducts, and colon.

  • Cholangiocarcinoma (CCA): This is cancer of the bile ducts. The lifetime risk for a person with PSC is estimated to be between 10% and 20% [3][4]. Because this cancer can be difficult to detect in its early stages, regular imaging is vital [5].
  • Gallbladder Cancer: People with PSC have a significantly higher risk of gallbladder cancer than the general population, with a lifetime risk of approximately 2% [6][7].
  • Colorectal Cancer (CRC): For those who have both PSC and Inflammatory Bowel Disease (IBD), the risk of colon cancer is much higher than for those with IBD alone [8][9].

Surveillance Methods

Doctors use a combination of imaging and blood tests to monitor your health.

MRI and MRCP

The “gold standard” for monitoring the bile ducts is Magnetic Resonance Cholangiopancreatography (MRCP) [10]. This specialized MRI is superior to ultrasound for detecting early-stage changes in the bile ducts [1]. Most specialists recommend an MRI/MRCP every 6 to 12 months [11][6].

CA 19-9 Blood Test

CA 19-9 is a “tumor marker” measured in the blood. While it is not a perfect test—it can be elevated by simple infections or blockages—doctors look for rapid or significant increases over time [12][13]. A sudden spike can be a “red flag” that triggers further investigation, such as an ERCP [14].

  • Note: About 10% of the population is “Lewis antigen negative” and cannot produce CA 19-9; for these patients, the test is not useful [15].

Gallbladder Polyps: A Different Rule

In the general population, small gallbladder polyps (under 10mm) are often just monitored. However, in PSC, any polyp carries a higher risk of being cancerous [11]. Many experts recommend gallbladder removal (cholecystectomy) if a polyp reaches 8mm or larger, or if it shows any growth between scans [11].

Surveillance Schedule

This table summarizes the standard monitoring recommendations for an adult with PSC:

Target Area Method Frequency Why?
Bile Ducts (CCA) MRI/MRCP + CA 19-9 Every 6–12 months Early detection of ductal changes [11]
Gallbladder Ultrasound or MRI Every 6–12 months Screen for polyps or wall thickening [6]
Colon (CRC) Colonoscopy Annual (if IBD is present) High risk of “right-sided” colon cancer [16]
Liver Health FibroScan / Blood Labs Every 6–12 months Monitor for progression to cirrhosis [10]
Bone Density DEXA Scan Baseline & Periodically PSC impairs absorption of fat-soluble vitamins (like Vitamin D), increasing the risk of osteoporosis.

The Importance of “Chromoendoscopy”

Because PSC-related colon cancer often grows as flat lesions that are hard to see, specialists recommend chromoendoscopy [17]. During this procedure, a blue or indigo dye is sprayed onto the colon wall to highlight abnormal areas, making them much easier for the doctor to find and biopsy [18][19].

By sticking to this schedule, you and your medical team can stay ahead of the disease and make informed decisions about your care.

Frequently Asked Questions

What types of cancer does PSC increase the risk of?
People with PSC have a significantly higher risk of developing cholangiocarcinoma (bile duct cancer), gallbladder cancer, and colon cancer. The risk for colon cancer is especially high for patients who also have Inflammatory Bowel Disease (IBD).
How often should I get an MRCP for my PSC?
Most specialists recommend that adults with PSC have a Magnetic Resonance Cholangiopancreatography (MRCP) every 6 to 12 months. This specialized MRI is considered the gold standard for monitoring the bile ducts and catching early-stage changes.
What is the CA 19-9 blood test used for in PSC?
CA 19-9 is a tumor marker measured through a blood test. Doctors track these levels over time to watch for rapid or significant increases, which can be an early warning sign of bile duct cancer and prompt further investigation.
When should a gallbladder polyp be removed if I have PSC?
In PSC, any gallbladder polyp carries a higher risk of being cancerous compared to the general population. Experts generally recommend surgery to remove the gallbladder if a polyp reaches 8mm or larger, or if it shows any growth between your regular scans.
Why do I need a chromoendoscopy instead of a regular colonoscopy?
Chromoendoscopy is a specialized colonoscopy technique where a dye is sprayed onto the colon wall. Because PSC-related colon cancer often grows as flat, hard-to-see lesions, this dye highlights abnormal areas so your doctor can easily find and biopsy them.

Questions for Your Doctor

  • • Since my lifetime risk of cholangiocarcinoma is between 10% and 20%, what specific imaging schedule—every 6 or 12 months—do you recommend for me?
  • • Am I 'Lewis antigen negative'? If so, should we still be using the CA 19-9 blood test for my cancer screening?
  • • If my CA 19-9 level jumps significantly in a single year, what will be our next diagnostic step?
  • • My MRCP shows a small gallbladder polyp. Given that PSC increases my risk for gallbladder cancer, at what size would you recommend surgery to remove it?
  • • Since I have both PSC and IBD, can we perform my annual colonoscopy using 'chromoendoscopy' (dye) to better detect flat, precancerous lesions?

Questions for You

  • • Have I had my baseline colonoscopy yet to check for 'silent' IBD, even if I have no bowel symptoms?
  • • Am I keeping a folder of my past MRCP reports and CA 19-9 levels so I can track any 'relative changes' over time with my doctor?
  • • Have I noticed any new or worsening symptoms like yellowing of the skin (jaundice), unintentional weight loss, or pain in my upper right abdomen?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Early Cholangiocarcinoma Detection With Magnetic Resonance Imaging Versus Ultrasound in Primary Sclerosing Cholangitis.

    Eaton JE, Welle CL, Bakhshi Z, et al.

    Hepatology (Baltimore, Md.) 2021; (73(5)):1868-1881 doi:10.1002/hep.31575.

    PMID: 32974892
  2. 2

    Impact on follow-up strategies in patients with primary sclerosing cholangitis.

    Bergquist A, Weismüller TJ, Levy C, et al.

    Liver international : official journal of the International Association for the Study of the Liver 2023; (43(1)):127-138 doi:10.1111/liv.15286.

    PMID: 35535655
  3. 3

    Primary sclerosing cholangitis.

    Rabiee A, Silveira MG

    Translational gastroenterology and hepatology 2021; (6()):29 doi:10.21037/tgh-20-266.

    PMID: 33824933
  4. 4

    The Microbiome and Primary Sclerosing Cholangitis.

    Ali AH, Carey EJ, Lindor KD

    Seminars in liver disease 2016; (36(4)):340-348 doi:10.1055/s-0036-1594007.

    PMID: 27997974
  5. 5

    MR imaging and cholangiography show suboptimal performance for diagnosing ductal cholangiocarcinoma in primary sclerosing cholangitis patients.

    Buhot Q, Bui Q, Chekir H, et al.

    European radiology 2025; (35(10)):6544-6553 doi:10.1007/s00330-025-11606-0.

    PMID: 40285814
  6. 6

    An update on cancer risk and surveillance in primary sclerosing cholangitis.

    Horsley-Silva JL, Rodriguez EA, Franco DL, Lindor KD

    Liver international : official journal of the International Association for the Study of the Liver 2017; (37(8)):1103-1109 doi:10.1111/liv.13354.

    PMID: 28028930
  7. 7

    Risk of Intestinal and Extraintestinal Malignancies in Inflammatory Bowel Disease With and Without Primary Sclerosing Cholangitis.

    Al Ta'ani O, Alsakarneh S, Shaukat A, et al.

    Digestive diseases and sciences 2025; doi:10.1007/s10620-025-09593-9.

    PMID: 41329382
  8. 8

    Clinical Outcomes in Patients with Primary Sclerosing Cholangitis With and Without Inflammatory Bowel Disease.

    Ibrahim A, Rockey DC

    Digestive diseases and sciences 2026; doi:10.1007/s10620-026-09699-8.

    PMID: 41649752
  9. 9

    Concurrent inflammatory bowel disease and primary sclerosing cholangitis: a review of pre- and post-transplant outcomes and treatment options.

    Hatami B, Pasharavesh L, Sharifian A, Zali MR

    Gastroenterology and hepatology from bed to bench 2023; (16(3)):259-269 doi:10.22037/ghfbb.v16i2.2589.

    PMID: 37767322
  10. 10

    Non-invasive diagnosis and follow-up of primary sclerosing cholangitis.

    Chazouillères O, Potier P, Bouzbib C, et al.

    Clinics and research in hepatology and gastroenterology 2022; (46(1)):101775 doi:10.1016/j.clinre.2021.101775.

    PMID: 34332142
  11. 11

    AGA Clinical Practice Update on Surveillance for Hepatobiliary Cancers in Patients With Primary Sclerosing Cholangitis: Expert Review.

    Bowlus CL, Lim JK, Lindor KD

    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2019; (17(12)):2416-2422 doi:10.1016/j.cgh.2019.07.011.

    PMID: 31306801
  12. 12

    An Unusual Case of Intrahepatic Stone Masquerading as Cholangiocarcinoma.

    Williams AS, Sikes MA, Liu S

    ACG case reports journal 2025; (12(2)):e01607 doi:10.14309/crj.0000000000001607.

    PMID: 39916889
  13. 13

    Carbohydrate Antigen (CA 19-9) Surge: Unraveling the Enigma of Elevated Levels in the Setting of Benign Etiologies.

    Ansari N, Ozgur SS, Besada D, et al.

    Cureus 2024; (16(4)):e57469 doi:10.7759/cureus.57469.

    PMID: 38699139
  14. 14

    Longitudinal analysis of CA19-9 reveals individualised normal range and early changes before development of biliary tract cancer in patients with primary sclerosing cholangitis.

    Wannhoff A, Brune M, Knierim J, et al.

    Alimentary pharmacology & therapeutics 2019; (49(6)):769-778 doi:10.1111/apt.15146.

    PMID: 30687954
  15. 15

    Inflammation But Not Biliary Obstruction Is Associated With Carbohydrate Antigen 19-9 Levels in Patients With Primary Sclerosing Cholangitis.

    Wannhoff A, Rupp C, Friedrich K, et al.

    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2015; (13(13)):2372-9.

    PMID: 26192140
  16. 16

    Primary sclerosing cholangitis associated with inflammatory bowel disease: an update.

    Rossi RE, Conte D, Massironi S

    European journal of gastroenterology & hepatology 2016; (28(2)):123-31 doi:10.1097/MEG.0000000000000532.

    PMID: 26636407
  17. 17

    Dye-based chromoendoscopy detects more neoplasia than white light endoscopy in patients with primary sclerosing cholangitis and IBD.

    Motta RV, Gupta V, Hartery K, et al.

    Endoscopy international open 2024; (12(11)):E1285-E1294 doi:10.1055/a-2437-8102.

    PMID: 39534278
  18. 18

    Recent advances in surveillance colonoscopy for dysplasia in inflammatory bowel disease.

    Na SY, Moon W

    Clinical endoscopy 2022; (55(6)):726-735 doi:10.5946/ce.2022.132.

    PMID: 36397275
  19. 19

    From random to precise: updated colon cancer screening and surveillance for inflammatory bowel disease.

    Fatakhova K, Rajapakse R

    Translational gastroenterology and hepatology 2024; (9()):27 doi:10.21037/tgh-23-36.

    PMID: 38716215

This page provides educational information about PSC surveillance and cancer risks. It is not a substitute for professional medical advice. Always consult your hepatologist or gastroenterologist to determine the right screening schedule for you.

Stay up to date

Get notified when new research about Primary sclerosing cholangitis is published.

No spam. Unsubscribe anytime.